Barclays PLC Raises Holdings in Tilray Inc (NASDAQ:TLRY)

Barclays PLC lifted its stake in shares of Tilray Inc (NASDAQ:TLRY) by 600.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 204,144 shares of the company’s stock after buying an additional 174,997 shares during the quarter. Barclays PLC’s holdings in Tilray were worth $359,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Ferguson Wellman Capital Management Inc. purchased a new position in shares of Tilray during the third quarter worth about $26,000. International Assets Investment Management LLC increased its stake in shares of Tilray by 335.3% during the third quarter. International Assets Investment Management LLC now owns 23,639 shares of the company’s stock worth $42,000 after acquiring an additional 18,208 shares during the period. Vista Capital Partners Inc. acquired a new stake in shares of Tilray in the 3rd quarter valued at approximately $42,000. Capital Management Associates Inc purchased a new stake in shares of Tilray during the 3rd quarter worth $45,000. Finally, Pallas Capital Advisors LLC boosted its holdings in Tilray by 58.1% during the third quarter. Pallas Capital Advisors LLC now owns 31,646 shares of the company’s stock worth $52,000 after buying an additional 11,632 shares in the last quarter. Institutional investors and hedge funds own 9.35% of the company’s stock.

Insider Buying and Selling

In other news, CFO Carl A. Merton purchased 26,000 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were acquired at an average cost of $1.36 per share, with a total value of $35,360.00. Following the transaction, the chief financial officer now owns 26,000 shares in the company, valued at approximately $35,360. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.87% of the company’s stock.

Analyst Ratings Changes

TLRY has been the topic of several research reports. Roth Mkm lowered their target price on Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a report on Friday, October 11th. Canaccord Genuity Group lifted their price objective on Tilray from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $2.70.

Tilray Price Performance

TLRY opened at $1.20 on Monday. Tilray Inc has a 52-week low of $1.14 and a 52-week high of $2.97. The company has a market cap of $1.08 billion, a P/E ratio of -4.00 and a beta of 2.08. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08. The company has a 50 day moving average of $1.32 and a two-hundred day moving average of $1.60.

Tilray (NASDAQ:TLRY) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.07). The firm had revenue of $210.90 million for the quarter, compared to analysts’ expectations of $216.34 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, analysts expect that Tilray Inc will post -0.14 earnings per share for the current year.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.